Please assess the completion status of the following clinical trial:

Trial Title: Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologic proof of adenocarcinoma of the prostate with clinical evidence of metastatic disease to the bone.~* Castrate resistant progression of prostate carcinoma, as shown by:~  * Serum testosterone level \<50 ng/dL or prior bilateral orchiectomy. Treatment to maintain castrate levels of testosterone should continue, and~    * Either symptomatic progression, or, if patient is asymptomatic then a rising serum PSA in two occasions at least 1 week apart, with minimum pre-treatment serum PSA of 5 ng/dL.~* Patients with nodal disease are eligible.~* Bi-dimensionally measurable disease within the bone.~* Life expectancy of at least 12 weeks.~* ECOG Performance status \< 2~* Adequate:~  * Bone marrow function; absolute neutrophil count \> 1,500 mm3, platelet count of \> 100,000 mm3 and hemoglobin \> 9.0 gm/dl.~ * Hepatic function; SGOT/SGPT and conjugated bilirubin less than twice the upper limit of normal.~ * Renal function; serum creatinine ≤ 2 mg/dL (or, if creatinine \> 2 mg/dL, then a creatinine clearance of at least 35 ml/min (measured or estimated by the Cockroft formula:~CLcr = \[(140-age) x wt (kg)\]/\[72 x serum creatinine (mg/dL)\].~* No evidence of coagulopathy as indicated by PT \< 1.5X upper limit of normal.~* Serum calcium (corrected) from 8 to11.5 mg/dL (2 to 2.9 mmol/L) - Patients must sign an informed consent indicating that they are aware of the investigational nature of the study.~Exclusion Criteria:~* Patients with variant histologies (e.g., ductal or small cell carcinoma).~* Patients with visceral disease are ineligible.~* Patients who have had prior Sipuleucel-T, docetaxel, cabazitaxel, abiraterone or enzalutamide as a single agent, or in combination therapy.~* Concurrent cancer chemotherapy, radiotherapy or surgery.~* Concurrent serious infection.~* Life threatening illness (e.g., congestive heart failure, uncontrolled angina or myocardial infarction in the prior six months).~* Hypertension uncontrolled by medication.~* Patients who are known to require invasive dental procedures.~* No known or suspected brain metastases (NOTE: patients with treated epidural disease are allowed)~* Administration of any investigational drug within 28 days prior to receipt of denosumab.~* Age ≤ 18 years of age

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Alliance A031201 (Type: ACTIVE_COMPARATOR): Denosumab plus enzalutamide, abiraterone and prednisone
- Standard of Care (Type: ACTIVE_COMPARATOR): Denosumab plus enzalutamide alone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues